Log In
Print this Print this

AMG 333

  Manage Alerts
Collapse Summary General Information
Company Amgen Inc.
DescriptionNot disclosed
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I
Standard IndicationMigraine
Indication DetailsTreat migraine
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today